drugset / Trial / NCT04045327

Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock

NCT04045327 ↗

Phase 3 Completed 105 enrolled Pharmazz, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a prospective, multi-centric, randomized, double-blind, parallel, controlled phase-III efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock. Centhaquine (previously used names, centhaquin and PMZ-2010; International Non-proprietary Name (INN) recently approved by WHO is centhaquine) has been found to be an effective resuscitative agent in rat, rabbit and swine models of hemorrhagic shock, it decreased blood lactate, increased mean arterial pressure, cardiac output, and decreased mortality. An increase in cardiac output during resuscitation is mainly attributed to an increase in stroke volume. Centhaquine acts on the venous α2B-adrenergic receptors and enhances venous return to the heart, in addition, it produces arterial dilatation by acting on central α2A-adrenergic receptors to reduce sympathetic activity and systemic vascular resistance.

Timeline

Start
2019-01-31
Primary completion
2019-09-23
Completion
2019-09-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Centhaquine Unknown 0.01 mg/kg Intravenous

Indications

No indication recorded.